SOM Biotech announces the election of Silvia Panigone as Executive Chair with the mission to prepare the company for a listing on the NASDAQ

Barcelona, Spain, March 26th, 2024. SOM Biotech (SOM), a clinical-stage drug discovery and development company based on a unique and proprietary Artificial Intelligent (AI) platform, appoints Silvia Panigone PhD, MBA as Executive Chair of the Board of SOM.

Dr Raul Insa, Founder and President of the Board at SOM "We are pleased and honored to have Silvia Panigone, joining SOM as Executive Chair. She brings to SOM an important and extensive experience in the Corporate Strategy at global level having served as CEO, COO and other C-level positions in private and public biotech and pharma companies as well as having served as Director in Investment Banking firms and Venture Capitalist groups".

"I thank Raul and SOM Board for the privilege to fulfill this role and I am enthusiastic to support the Company in its next growth step, said Silvia Panigone. "My goal is to strengthen SOM's Corporate Governance, to open to the US market and prepare it for a possible listing on the NASDAQ within the next couple of years to establish a US presence. I have been following SOM for several years as a small investor and I appreciated the uniqueness of SOM's AI platform with its high, demonstrated, clinical predictivity and the strong commitment and dedication of Raul and his team. I will do my upmost best to make SOM Biotech successful for the benefit of patients and all of SOM's stakeholders".

About SOM Biotech: SOM Biotech (www.sombiotech.com), headquartered in Barcelona, Spain, is a biopharmaceutical company founded in 2009. It is based on a unique proprietary AI platform (*SOM^{AI}PRO*) to identify new mechanisms of action of existing small molecule drugs for the treatment of diseases of high unmet medical need with a focus on orphan disorders of the CNS. *SOM^{AI}PRO* is the only AI drug discovery platform whose products have achieved positive Phase II outcomes in patients, demonstrating the high clinical predictive value of the platform. SOM leverages on an extensive pipeline of products developed for the treatment of orphan indications including Transthyretin Amyloidosis, chorea in Huntington's disease, Phenylketonuria, Duchenne Muscular Dystrophy and Tardive Dyskinesia. The Transthyretin Amyloidosis product was out-licensed upon positive Phase IIa data.

SOM is led by an experienced team with a successful track record in both drug development and AI platforms development.

For more information about SOM Biotech, please contact:
info@sombiotech.com